Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -6.29%39 Days Inventory is 177.72 as of Mar. 2026, which is 39% above its 10-year median of 127.68. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Standard BioTools ranks worse than 63.71% on this metric.
The historical rank and industry rank for Standard BioTools's Days Inventory or its related term are showing as below:
STU:FLB'
s Days Inventory Range Over the Past 10 Years
Min: 92.65 Med: 127.68 Max: 218.88
Current: 218.88
During the past 13 years, Standard BioTools's highest Days Inventory was 218.88. The lowest was 92.65. And the median was 127.68.
STU:FLB's Days Inventory is ranked worse than 63.71% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 179.115
vs STU:FLB: 218.88
Standard BioTools's Days Inventory
declined
from Mar. 2025 (316.05) to Mar. 2026 (177.72).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Standard BioTools's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Standard BioTools's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.91.
Standard BioTools (STU:FLB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Standard BioTools's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Standard BioTools's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Standard BioTools Days Inventory Related Terms
Standard BioTools Days Inventory Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: Days Inventory Comparison
For the Medical Devices subindustry, Standard BioTools's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Days Inventory distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a Days Inventory of 177.72 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Standard BioTools and its competitors. This is 39% above median its historical median of 127.68. Over the past decade, Standard BioTools' Days Inventory has ranged from 92.65 to 218.88. According to the industry distribution chart, Standard BioTools ranks #502 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 63.7%.
Is Standard BioTools' Days Inventory too high?
Standard BioTools' current Days Inventory of 177.72 is 39% above median its 10-year median of 127.68. Over the past 10 years, this metric has ranged from a low of 92.65 to a high of 218.88. The Medical Devices & Instruments industry median Days Inventory is 179.12. Standard BioTools' value of 177.72 is 0.8% below this industry median. Based on the distribution chart, Standard BioTools ranks #502 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Days Inventory compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #502 out of 788 companies for Days Inventory. This places Standard BioTools in the lower half of its industry. The industry median Days Inventory is 179.12. Standard BioTools' value of 177.72 is 0.8% below this benchmark. Historically, Standard BioTools' own Days Inventory has ranged from 92.65 to 218.88 over the past decade. While the company's 10-year median is 127.68 vs. the industry median of 179.12, Standard BioTools has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.12, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Days Inventory of 177.72 is 0.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Days Inventory is 177.72, which is 39% above median its own 10-year median of 127.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current Days Inventory is 177.72, which is 39% above median its 10-year median of 127.68 and 0.8% below the Medical Devices & Instruments industry median of 179.12. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Days Inventory is 177.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Days Inventory: 177.72 (39% above median its 10-year median of 127.68)
GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
Industry Position: 0.8% below the Medical Devices & Instruments median (#502 of 788)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score
Get the complete analysis for STU:FLB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
